This clinical trial is focused on studying ulcerative colitis, a condition that causes inflammation and sores in the digestive tract. The trial will use a medication called adalimumab, which is also known by the brand name Humira. This medication is given as a solution for injection under the skin. The purpose of the study is to compare the usual care for ulcerative colitis with a new approach that includes setting specific treatment goals, using telemonitoring (remote health monitoring through technology), and providing patient education.

Participants in the study will be randomly assigned to one of two groups. One group will receive the standard treatment for ulcerative colitis, while the other group will follow the new approach. This new approach involves regular monitoring of a substance called fecal calprotectin at home, which helps track inflammation levels, along with educational support to help manage the condition. The study will last for 48 weeks, during which the effectiveness of the treatments will be assessed.

The trial aims to see if the new approach can lead to better outcomes, such as achieving remission, which means the symptoms of ulcerative colitis are reduced or disappear. The study will also look at other factors like quality of life, patient satisfaction, and the number of hospital visits related to ulcerative colitis. Participants will be monitored for safety and how well they tolerate the treatment. The results will help determine if the new approach is more effective than the standard treatment for managing ulcerative colitis.